



ESMO ADVANCED COURSE MELBOURNE AUSTRALIA 25-26 OCTOBER 2022

Chairs:

Solange Peters, Switzerland Ben Solomon, Australia

ESMO ADVANCED COURSE PROGRAMME

EARLY STAGE NSCLC

Melbourne, Australia 25-26 October 2022

CO-CHAIRS:

Solange Peters, Switzerland Ben Solomon, Australia

SPEAKERS:

Emma Dean, Australia Christian Finley, Canada Fiona Hegi-Johnson, Australia Lizza Hendriks, Netherlands Rina Hui, Australia Thomas John, Australia Natasha Leighl, Canada Fiona McDonald, United Kingdom Annette McWilliams, Australia David Planchard, France Daniel Steinfort, Australia Emily Stone, Australia Daniel S. W. Tan, Singapore Sarah L. White, Australia Gavin Wright, Australia

LEARNING OBJECTIVES

- Understanding screening opportunity and the need for implementation
- Knowing about standard optimal diagnostic tools
- Learning about innovation in the multimodality radical treatment of early NSCLC
- Anticipating the role for IO in early NSCLC

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland

Email: courses@esmo.org

www.esmo.org



Tuesday, 25 October 2022

09:00-09:10	Welcome and introduction Solange Peters, CH Ben Solomon, AU
09:10-10:25	Session 1 - Changing incidence of smoking & prevention
20'	Impact of public health measures: Falling incidence of smoking? Sarah L. White, AU
20'	Rise of vaping: Is it better than smoking? Emily Stone, AU
20'	Smoking cessation: What works? Emma Dean, AU
15'	Discussion
10:25-11:20	Session 2 - Screening for lung cancer — the NELSON trial and implications for implementation of screening
20'	The NELSON trial and implications for implementation of screening Christian Finley, CA
20'	Screening in Australia and across continents Annette McWilliams, AU
15'	Discussion
11:20-11:50	Coffee break
11:50-12:45	Session 3 - Diagnosis and initial management of early stage lung cancer
20'	New bronchoscopic approaches to biopsy and staging Daniel Steinfort, AU
20'	What else do you need to know about your patient before TB decision? (cardio-respiratory functions,
	comorbidities, PS, patients' preferences) Emily Stone, AU
15'	· · · · · · · · · · · · · · · · · · ·
15' 12:45-13:45	Emily Stone, AU
	Emily Stone, AU Discussion
12:45-13:45	Emily Stone, AU Discussion Lunch
12:45-13:45 13:45-15:00	Emily Stone, AU Discussion Lunch Session 4 - Management of early stage lung cancer - New surgical techniques RATS vs VATS New surgical techniques RATS vs VATS & lung-sparing surgery
12:45-13:45 13:45-15:00 20'	Emily Stone, AU Discussion Lunch Session 4 - Management of early stage lung cancer - New surgical techniques RATS vs VATS New surgical techniques RATS vs VATS & lung-sparing surgery Gavin Wright, AU The current role of SABR and perspectives
12:45-13:45 13:45-15:00 20' 20'	Emily Stone, AU Discussion Lunch Session 4 - Management of early stage lung cancer - New surgical techniques RATS vs VATS New surgical techniques RATS vs VATS & lung-sparing surgery Gavin Wright, AU The current role of SABR and perspectives Fiona McDonald, UK Detection of minimal residual disease after surgery or (chemo)radiation by cfDNA

15:30-16:45	Session 5 - Incorporation of immunotherapy with radical approaches for early NSCLC
20'	Perspective for adjuvant immunotherapy Solange Peters, CH
20'	Immunotherapy as a neoadjuvant component Ben Solomon, AU
20'	Management of locally advanced NSCLC: Role of immunotherapy (PACIFIC study) Fiona McDonald, NL
15'	Discussion
19:30	Networking dinner

Wednesday, 26 October 2022

09:00-12:30 Workshop sessions

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all sessions on a rotation basis)

25' Introduction based on clinical cases presented by speakers

30' Discussion 5' Break

Workshop 1 Management of N2 Disease: Chemoradiation followed by IO vs Induction chemo/IO prior to surgery

60' Fiona Hegi-Johnson, AU Natasha Leighl, CA

Gavin Wright, AU

Workshop 2 Management of toxicities observed in the curative setting: When to stop, how to treat, can I resume?

60' Lizza Hendriks, NL Rina Hui, AU

Workshop 3 How to treat early EGFR/oncogene-addicted NSCLC today?

Thomas John, AU

David Planchard, FR Daniel S. W. Tan, SG

11:00-11:30 Coffee break

11:30-12:30 Workshops continuation

12:30-13:00 Feedback on the workshops from each group

13:00-13:15 Synthesis and wrap-up

Solange Peters, CH Ben Solomon, AU

13:15-14:15 Lunch